Balaxi Pharmaceuticals (BALAXI) Q3 25/26 earnings summary

Executive summary

• Achieved strong sequential revenue recovery in Q3 FY26, up 29% QoQ to ₹72.54 crore, but down 1% YoY due to Angola market challenges and extended working capital cycles in institutional and hospital segments.

• Gross profit margin moderated to above 42% (vs. 48% YoY), with bottom line declining to ₹0.31 crore from ₹5.36 crore YoY, mainly due to elevated operating costs from strategic market shifts.

• Significant operational progress on the new pharmaceutical formulation facility in Hyderabad/Jadcherla, with audit readiness and successful validation completed.

• Standalone and consolidated unaudited financial results for Q3 and nine months ended 31.12.2025 were approved and released, with statutory auditor review completed.

• LATAM region emerged as a key growth driver, supported by a robust order pipeline and 13 new product registrations, totaling 948 across geographies.

Financial highlights

• Q3 FY26 consolidated revenue at ₹72.54 crore, up 29% QoQ but down 1% YoY; gross profit at ₹30.81 crore, up 4.6% YoY.

• Gross margin improved by 229 bps YoY to 42.5%; EBITDA at ₹3.19 crore, down 59.8% YoY; EBITDA margin at 4.4%, down 642 bps.

• PAT at ₹0.31 crore, down 94.3% YoY; PAT margin at 0.4% vs. 7.3% YoY; EPS at ₹0.06, down 93.8% YoY.

• FY25 revenue grew 21.2% YoY to ₹292.56 crore; gross profit up 12.6% to ₹126.86 crore; gross margin at 43.4% (down 331 bps YoY).

• FY25 EBITDA at ₹33.50 crore (down 24% YoY); PAT at ₹25.07 crore vs. loss of ₹2.39 crore in FY24, which included a one-time FX loss in Angola.

Outlook and guidance

• Management anticipates margin recovery and sustainable long-term growth, driven by improved regional traction, operating leverage, and the new Hyderabad facility.

• The Jadcherla formulation facility is fully prepared for regulatory inspection, indicating potential for future revenue growth from new manufacturing capabilities.

• Robust order pipeline in LATAM expected to support top-line growth in coming quarters.